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Background: Cyclooxygenase (COXs) and Lipoxygenase (LOXs) pathways are the two major enzymatic pathways in
arachidonic acid (AA) metabolism. The term eicosanoid is used to describe biologically active lipid mediators
including prostaglandins, thromboxanes, leukotrienes and other oxygenated derivatives, which are produced
primarily from AA. Eicosanoids generated in a tissue specific manner play a key role in inflammation and cancer. As
AA is the substrate common to variety of COXs and LOXs, inhibition of one pathway results in diversion of the
substrate to other pathways, which often is responsible for undesirable side effects. Hence there is need for
development of not only isozyme specific inhibitors but also dual/multi enzyme inhibitors. Understanding the
interactions of AA and characterizing its binding sites in these enzymes therefore is crucial for developing enzyme
specific and multi enzyme inhibitors for enhancing therapeutic efficacy and/or overcoming side effects.
Results: AA binding sites in COXs and LOXs are identified and compared by the development of receptor based
pharmacophore using MultiBind. Physico chemical properties were compared to understand the details of the
binding sites in all the enzymes and to elucidate important amino acids that can be targeted for drug design. The
alignment of AA binding sites in the seven enzymes COX-1, COX-2, 5-LOX, 12-LOX, 15-LOX and plant soybean LOX-1
and LOX-3 indicated a common pattern of five common interacting groups. In the same way, comparison of AA
binding sites was done pair wise and by multiple alignment in various combinations. It has been identified that
aliphatic and aromatic interactions are the most common in all the enzymes. In addition interactions unique to each
one of these enzymes were identified.
Conclusion: The complete analysis of AA binding sites in the seven enzymes was performed; 120 combinations for the
seven enzymes were studied in detail. All the seven enzymes are structurally quite different, yet they share AA as the
common binding partner. Comparisons in various combinations showed how they are similar and dissimilar with each
other. This information will be helpful in designing specific as well as common inhibitors.
Keywords: Cyclooxygenase, Lipoxygenase, Arachidonic acid, Specific inhibitors, Receptor based pharmacophore, Drug
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Arachidonic acid (AA), the major polyunsaturated fatty
acid (PUFA) present in mammalian systems, is oxygen-
ated by three important pathways – the cyclooxygenase
(COX), the lipoxygenase (LOX) and the epoxygenase, to
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unless otherwise stated.(PGs), leukotrienes (LTs), and epoxyeicosatrienoic acids
(EETs), collectively called as eicosanoids [1].
COX is a bifunctional heme containing enzyme that
catalyzes the biosynthesis of PGs from AA. It is bifunc-
tional enzyme and exhibits cyclooxygenase and perox-
idase activities. It introduces two molecules of oxygen
into AA to form PGG2, a cyclic hydroperoxy endoperox-
ide, which is subsequently reduced by peroxidase to give
hydroxy endoperoxide, PGH2 [2]. There are three COX
isoforms, COX-1, COX-2, and COX-3 [1-3]. COX-1,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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low levels, and is presumed to function primarily in the
maintenance of physiological functions [4-7]. The indu-
cible isoform of COX, COX-2 is induced by several and
plays a direct role in inflammation, cancer and various
other diseases [8,9]. COX-3, a product of COX-1 gene has
been identified as the alternatively spliced form found
mostly in the brain.
The other important group of enzymes involved in
AA metabolism, LOXs, are closely related non-heme
iron containing dioxygenases which catalyze the
addition of molecular oxygen to form hydroperoxy
metabolites (HPETEs). LOXs are broadly classified as 5-,
12, and 15-LOXs in animals [10,11] based on regio and
stereo specific incorporation of molecular oxygen on
AA. In plants, LOXs are classified as 9- and 13-LOXs
based on the regio specific incorporation of oxygen on
Linoleic (LA) or α–Linolenic acids [12]. Eicosanoids
generated by these LOXs in a tissue specific manner play
key role in various diseases. In various LOX isoforms the
active sites have modifications to effect specific reactions
but the basic enzyme structures are conserved [13-16].
Hence it is very important to identify important con-
served/non-conserved amino acids at the active sites of
these LOXs.
Non steroidal anti-inflammatory drugs (NSAIDs) are
the most commonly used remedies for arthritis and
some inflammation associated diseases. A most promis-
ing approach seemed to be the preparation of novel
NSAIDs specific for the COX-2 (COXIBs) which does
not inhibit COX-1 effectively hence devoid of gastro-
intestinal toxicity associated with non-specific COX-1/
COX-2 inhibitors. These COXIBs, however were shown
to have cardiac side effects when used at high concentra-
tions for a long period. These side effects have been at-
tributed to the shift towards LOX pathway, hence an
alternative approach of developing COX-2/5-LOX dual
inhibitors (CLOXIBs) is recently being considered [17].
Licofelone, a COX-2/5-LOX dual inhibitor has success-
fully completed phase III trials and is demonstrated to
be safe and efficacious for standard treatments of osteo-
arthritis [18].
Development of specific inhibitors or dual inhibitors of
enzymes involved in AA metabolism is of great challenge.
Binding of the same substrate to LOX and COX enzymes
implies that there is a common microenvironment within
the catalytic sites of these enzymes, hence designing an
inhibitor which interacts specifically with one/two en-
zymes requires a detailed understanding of binding sites
of the substrate AA to these enzymes. The main objective
of this study is to compare binding site features in AA
metabolizing enzymes and to elucidate important amino
acids that can be targeted for drug design. In this study
five isoforms of LOX and two isoforms of COX enzymes(to generate reliable data enzymes having crystal data
alone were considered) collectively were considered for
the analysis. Even though there are COX-substrate struc-
tures available in Protein Data Bank (PDB), till date
there is no crystal structure for LOX-substrate complex.
Structural aspects of these enzymes were understood
using receptor based pharmacophore models and by
comparison of physicochemical properties at binding
site were performed. The present study will provide in-
sights into AA binding sites of these enzymes and may
form the basis for developing enzyme specific as well as
dual/multi enzyme targeting novel drugs. Multitarget
drug design is gaining prominence in modern drug dis-
covery and in silico approaches may play a very crucial
role in such approaches [19]. In this context this study




The hydrophobic nature of AA substrate suggests that
predominantly hydrophobic residues line the substrate-
binding pocket. To understand the AA binding sites of
LOXs in comparison with COXs, pair wise alignment
studies were performed. The binding sites were ini-
tially compared in a pair wise manner. Pair wise sur-
face alignments of the enzymes detect more common
features and help in the elucidation of important
amino acid similarities between members of same class
and also individually with enzymes of another family.
1. Comparison of the COXs : COX-1 – COX-2
COX, one of the pathways in AA metabolism is of
great therapeutic interest and a simple pubmed
search using the keyword ‘COX inhibitor’ retrieves
around 110000 articles showing the quantum of
research being carried out on these enzymes. As
mentioned earlier, COX-1 and COX-2 are members
of the same family and they share large similarity
with each other in their enzyme reaction with their
common substrate AA. Pairwise alignments of the
binding sites in MultiBind showed that they have
great similarity at the AA binding site. They were
scored 90.4106 with 36 similar features. The most
common features observed were aliphatic (ALI) and
aromatic pi contacts (PII). Apart from these, common
hydrogen bond donor (DON), hydrogen bond
acceptor (ACC) and mixed hydrogen bond donor and
acceptor (e.g. in histidine) (DAC) were also observed.
The common physico-chemical properties and the
contributing amino acids are shown in Additional file
1: Table S1. There are also different amino acids in
COX-1 and COX-2 sharing the same ALI feature.
Isoleucine in COX-1 is replaced with Valine in COX-2.
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site points at the binding site of the COXs, the size
difference in these amino acids, resulting in volume
differences at the active centre, is the only salient
distinction observed. This size difference has been
exploited successfully in designing COXIBs.
Celecoxib shows 375-fold selectivity towards
COX-2 over COX-1 [20]. Studies showed that the
primary factor contributing to the COX-2 selectivity
of celecoxib and related 1,5-diarylpyrazoles is the
substitution of Ile523 in COX-1 for Valine in COX-2
[21]. This shows that the differences and the common
features in arachidonic binding site with each one of
these enzymes can be exploited in the development of
selective as well as dual/multi enzyme inhibitors.
2. Comparison of COX-2 with Animal LOXs
Despite the relatively safe pharmacological profile of
the COXIBs like celecoxib and valdecoxib there is
concern regarding their use in patients with
emerging news of myocardial infarction on
prolonged use. This is due to the shift of the AA
towards LOX pathway because of inhibition of COX
pathway. Therefore, there is increasing need for
development of anti-inflammatory drugs with fewer/
no side effects. In this connection, various research
groups started working on dual COX-2/LOX
inhibitors (CLOXIBs) that would prevent the drift of
AA towards the other pathway [22]. In order to design
CLOXIBs the information of AA binding sites in theseFigure 1 Common physiochemical parameters identified for 5-LOX (white) and C
AA binding site are labeled.enzymes is very useful. The main focus of the study was
identify common features of COX-2 binding site with
5-LOX, 12-LOX and 15-LOX individually. The
patterns or important interactions observed will
further aid in planning drug design experiments.
The alignment of AA binding sites of COX-2 and
5-LOX produced a score of 33.43 in MultiBind with
15 common physicochemical properties. Common
ALI, PII, ACC and DAC interactions were observed.
Three amino acids Tyr, Phe and Leu are commonly
observed in AA binding site of both the enzymes. PII
interactions are more in number followed by ALI.
ACC and DAC features were observed, the ACC of
Gln363 in 5-LOX is comparable to Ser530 of COX-2
and DAC of His372 is comparable to Tyr355.
Though the hydrogen bond forming functional
groups are not of the same amino acids, they can be
helpful in the design of common inhibitors. The
complete list of amino acids and the common
physicochemical features are included in Additional
file 1: Table S2 and shown in Figure 1.
In comparison, AA binding sites of 12-LOX and
15-LOX were scored 32.68 and 41.89 respectively
with COX-2. The 10 common features, detected in
pairwise alignment of COX-2/12-LOX, have been
dominated by seven ALI features. Only one PII
contact was observed different from the case of
COX-2/COX-1 and COX-2/5-LOX. Unlike COX










Table 2 Pair wise alignments of 5-LOX binding site with
other LOXs using MultiBind
Compared proteins No. of detected features Score
5-LOX– 12-LOX 10 35.3112
5-LOX– 15-LOX 14 41.9221
5-LOX– LOX-1 8 24.9893
5-LOX– LOX-3 15 36.8885
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share 2 similar features for different amino acids.
Histidine in 12-LOX contributes DAC group
wherein Serine of COX-2 possesses ACC group; in
another feature, Histidine in 12-LOX contributes
DAC group wherein Glutamine in COX-2 supplies
ACC property. It is significant that 12-LOX has 2
additional donor properties compared to COX-2 due to
the presence of two DAC groups complimentary to
the ACC groups of COX-2.
The alignment between the AA binding sites of
15-LOX and COX-2 revealed that all amino acids
are different, sharing the same property except one.
Glycine possesses same property in both enzymes.
The amino acids contributing for the same
physicochemical properties are shown in Additional
file 1. As can be seen from the Table 1, the binding
site of 15-LOX shares more similarity with COX-2
than the other two LOXs based on the score. But
interestingly, 5-LOX has more common features
with COX-2 than the other LOXs.
3. Comparison of COX-2 with Plant LOXs
The two plant LOXs, soybean LOX-3 and soybean
LOX-1 had 11 and 8 common features with AA
binding site of COX-2 (Table 1). They are aligned
with scores 35.3228 and 19.6051 respectively. It can
be seen that animal LOXs are more similar to the
inducible COX-2 enzyme than plant LOXs.
4. Comparison of 5-LOX with other animal LOXs
The binding site of 5-LOX and 12-LOX have five
ALI features in common out of the ten common
physicochemical properties identified, indicating it to
be the most prominent property in the binding site.
Two PII interactions are also observed. Interestingly
charged amino acid Glu356 of 12-LOX is present
corresponding to Gln363 of 5-LOX. Both of them
act as ACC. The other prominent amino acid
differences are shown in Additional file 1. The
12-LOX was scored 35.31 when compared to 15-LOX
which had similarity score of 41.92 with 5-LOX as
shown in Table 2. Both 12 and 15-LOX had seven ALI
and three PII features in common, the replacement ofble 1 MultiBind data on pairwise alignments of COX-2
inding site with all six enzymes
mpared proteins No. of detected features Score
X-2 – COX-1 36 90.4106
X-2 – 5-LOX 15 33.4303
X-2 – 12-LOX 10 32.6815
X-2 – 15-LOX 12 41.8927
X-2 – LOX-1 8 19.6051
X-2 – LOX-3 11 35.3228charged amino acid Glu to Gln is also seen in
15-LOX. The high score of 15-LOX with 5-LOX is
because of the presence of seven identical amino acids
contributing for common interacting groups.
5. Comparison of 5-LOX with plant LOXs
In the two plant LOXs considered, Soybean LOX-3
showed 15 common features and Soybean LOX-1
showed 8 common features with the binding site of
5-LOX. They are aligned with scores 36.8885 and
24.9893 respectively. Based on this comparison, it
can be seen from the similarity score that AA binding
sites in plant LOXs share almost the same similarity
with animal 5-LOX and COX-2. Among the two plant
LOXs, LOX-3 has higher similarity with 5-LOX and
COX-2.
6. Comparison of COX-1 with all LOXs
Due to the high similarity between COX-2 and
COX-1, development of COX-2 inhibitors with less
affinity towards COX-1 is a big challenge. The binding
site of COX-1 was compared with that of the LOXs to
recognise the structurally conserved physicochemical
patterns. The animal LOXs, 5-LOX, 12-LOX and 15-
LOX showed 14, 10 and 11 common features with
scores of 33.04, 31.34 and 31.45 respectively. Soybean
LOX-3 and soybean LOX-1 had 12 and 9 common
features with scores of 36.54 and 23.20 respectively.
The studies showed that the binding sites of COX-1
have less similarity with LOXs when compared with
COX-2. COX-1 has highest similarity with soybean
LOX-1 followed by 5-LOX whereas COX-2 has
maximum similarity with 15-LOX.
Multiple alignments
Multiple alignment of 3–7 binding sites were performed.
The physicochemical similarities observed in various
combinations are included in Additional file 1 and some
of the alignments are discussed below:
1. All animal LOXs
The multiple surface alignment of all the three
binding sites of animal LOXs indicated a common
pattern of eight physiochemical properties, namely
one DAC, four ALI interactions, two ACC and one
PII contacts. Figure 2 lists the common
physiochemical parameters identified for each of the
Figure 2 Common physiochemical parameters identified for 5-LOX, 12-LOX and 15-LOX. The amino acids of 5-LOX (green), 12-LOX (red) and
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number followed by ACC.
2. COX-1, COX-2 and individual LOXs
The comparison of the COXs with individual
human LOXs was performed. It has been observed
that the number of features range from 6–13.
5-LOX has 13 common physicochemical parameters
with COXs where as sLOX-1 has only 6 common
features. Human LOXs were scored higher than
plant LOXs as seen in Table 3.
3. COX-1, COX-2 and all human LOXs
Alignment of the five binding sites of COXs and
animal LOXs indicated a common pattern of five
physicochemical properties. ALI interactions are
more in number in this multiple alignment. The
details are enclosed in Table 4.
4. All 7
Alignment of all the seven binding sites resulted in a
common pattern with five physicochemical
properties as shown in Figure 3, namely two ALI,
one PII and two ACC. The score obtained when
aligned was 21.0266.ble 3 Alignments of individual LOXs with COXs using
ultiBind





5LOX-COX1-COX2 13 45.4904Validation of COX-2/5-LOX and 5-LOX/15-LOX model
generated with docking studies
COX-2/5-LOX model generated was further validated
by docking studies with a known COX-2/5-LOX dual in-
hibitor, licofelone. As shown in Figure 4, the com-
pound formed interactions with amino acids that were
found to be important. The receptor models gener-
ated showed that the amino acids of both the proteins
5-LOX and COX-2 have common interacting groups
at the active site. Docking results supplemented the
models. The only charge group, the carboxyl moiety of
licofelone interacted with common DAC feature (Tyr
355 in COX-2 and His372 in 5-LOX). The hydropho
bic Cl group aligned at the common ALI feature (Val
523 in COX-2 and Leu 368 in 5-LOX). The aromatic
ring of licofelone formed strong PII interactions with
Trp 387 in COX-2 and Phe 421 in 5-LOX, in correla
tion with the common PII feature observed in the
model. The dimethylcyclopentane moiety formed
hydrophobic interactions with few common ALI features
observed. Hence, the docking results showed that the
model generated can be used to elucidate the common
features and can be further used in the design of dual in-
hibitors. There is a common hydrogen bond feature
close to the vicinity of licofelone corresponding to Tyr
385 in COX-2 and Thr 364 in 5-LOX. This site point
can be further used for lead optimization employing site
point connection method.
As discussed earlier, the 5-LOX and 15-LOX model
generated showed similar features at the binding site.
One of the binding features, ACC was contributed by
two different amino acids in both the enzymes, Glu in
Table 4 Common physiochemical parameters identified for COX-1, COX-2, 5-LOX, 12-LOX and 15-LOX
15-LOX 12-LOX 5-LOX COX-1 COX-2
A. A. Type A. A. Type A. A. Type A. A. Type A. A. Type
Glu 357 ACC Glu 356 ACC Gln 363 ACC Ser 530 DAC Ser 530 DAC
His 361 DAC His 360 DAC His 367 DAC Ala 527 DON Ala 527 DON
His 361 PII His 360 PII His 367 PII Gly 526 PII Gly 526 PII
Leu 362 ALI Leu 361 ALI Leu 368 ALI Met 522 ALI Met 522 ALI
Leu 408 ALI Val190 ALI Ile 415 ALI Leu 352 ALI Leu 352 ALI
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be mentioned that a functional group which interacts
with amide group of 5-LOX and repels with carboxylic
group in 15-LOX can be used to develop specific 5-LOX
inhibitor. To support this docking was performed with
ABT-761, a specific 5-LOX inhibitor. ABT-761 was
docked into the binding site of 5-LOX and 15-LOX and
its interactions were studied. As shown in the Figure 5,
ABT-761 aligns in the center of the binding site. The hy-
droxyl group of hydroxyurea formed strong hydrogenFigure 3 Licofelone in the binding site of A) COX-2 and B) 5-LOX.bond with the amide group of Gln 363. In 15-LOX, the
inhibitor did not bind at the binding site this may be
due to repulsion between carboxyl group of Glu 357 and
the inhibitor.
Discussion
The goal of drug discovery is to design exquisitely select-
ive ligands that act on a single disease target. The current
approach is that safer, more effective drugs will result
from designing very selective ligands where undesirable
Figure 4 Receptor based pharmacophore of all the LOXs and COXs was studied. Aliphatic groups are shown in grey; Acceptor groups are shown
in red; Donor/Acceptor groups are shown in blue; Aromatic pi contacts are shown in orange.
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target strategies have also gained importance in the recent
time. To design a specific or multitarget inhibitor it is very
important to know the binding site patterns in closely re-
lated pathways. In a recent study, Doble et al. have done a
comparative study of PGH2 binding site in prostaglandin
synthases [23]. Such studies would provide insights intoFigure 5 ABT-761 in the binding site of 5-LOX.the chemical features which can be exploited for selective/
multitemplate inhibitor design.
In the present study we aimed to understand the phys-
icochemical features unique or similar in AA metaboliz-
ing enzymes. It has been identified that in the COXs
there are 36 common features at the AA binding site, the
only difference at the binding sites was Val substitution in
Reddy et al. BMC Research Notes  (2015) 8:152 Page 8 of 10COX-2 for Ile in COX-1 at position 523. Previous
studies suggested that this small change in amino acid
provides additional space in COX-2 binding pocket.
The sulfonamoylphenyl or methylsulfonylphenyl moi-
eties of COXIBs can therefore be accommodated only
in the active site of COX-2. This supports that amino
acid differences at the common physicochemical pa-
rameters studied can contribute for the development
of specific/selective inhibitors.
The comparative study of human 5-LOX, 12-LOX
and 15-LOX has shown that there are 8 common fea-
tures, two common ACC, one DAC, one PI and four
ALI interaction groups. This is in correlation with the
previous reports on ligand based pharmacophore model
of 5-LOX developed by Aparoy et al. [14] and Charlier
et al. [24] where the significance of these four types of
interactions has been explained. The results obtained in
this study on multiple alignments of the binding sites
reveal that soybean LOX-1 is less similar with other
binding sites in other enzymes and its inclusion reduces
the score in all the alignments. COXs, however, have
very common interacting groups at the AA binding site.
Human LOXs have 10–15 common interacting groups.
5-LOX has maximum similarity score of 41.92 with
15-LOX and has 14 common features. In the pair wise
comparison of COX-2 with all LOXs individually, it has
been observed that COX-2 is more similar to human
LOXs than the plant isoforms. The benefits of develop-
ing CLOXIBs have been discussed earlier. To develop a
COX-2 inhibitor which would also bind to 5-LOX spe-
cifically is a great challenge. The pairwise studies of all
human LOXs individually with COX-2 showed that 15-
LOX has maximum complimentary score followed by
5-LOX. COX-2/5-LOX has 15 common features com-
pared to 12 common features in COX-2/15-LOX. The
less similarity of COX-2 and 5-LOX at binding site and
almost equivalent features among COX-2/5-LOX and
COX-2/15-LOX makes the design of dual inhibitors
concept more challenging. In our study, which is aimed
to provide insights into development of specific dual
inhibitors, various important differences/similarities at
binding sites have been identified. COX-2/5-LOX
pharmacophore model showed 15 common interactions
when compared to 12 interactions in COX-2/15-LOX
and 10 interactions in COX-2/12-LOX. COX-2/5-LOX
model has more PI interactions (6) in common followed
by ALI (5). The COX-2/15-LOX and COX-2/12-LOX
models have fewer PI interactions (1 and 2 respectively),
hence the amino acids at 5-LOX binding site Tyr181,
Phe359, Phe421, Trp599 can be targeted for aromatic
interactions which may increase specificity towards
COX-2/5-LOX.
The differences observed in the AA binding site of the
LOXs could be exploited for the development of potentialdual/multi inhibitors. A major difference that has been ob-
served in the receptor based pharmacophore models of
the human LOXs is that, amino acid Glu with acidic side
chain is replaced with Gln in 5-LOX. Rational design of
compounds which would interact effectively with Gln
than Glu can form potential specific 5-LOX inhibitors.
Even bulkier amino acid Ile 593 in 15-LOX is replaced
with smaller amino acid Ala in 5-LOX. A bulky hydropho-
bic group in the ligand can occupy the corresponding
space in 5-LOX. These differences can be taken advantage
of in the development of specific 5-LOX inhibitors as in
the case of COX-2 inhibitors.
Conclusions
The complete analysis of AA binding sites in the seven
enzymes was performed; 120 combinations for the seven
enzymes were studied in detail. All the seven enzymes
are structurally quite different, yet they share AA as the
common binding partner. Our comparative study shows
that there is no precise or specific pattern observed at
AA binding sites of the enzymes studied. It has been ob-
served that the most important features observed at the
active site (ALI and PII interactions) are in agreement
with the previous reports. Individually, when enzymes
were compared to each other, many common features
have been observed which can be exploited for design of
a molecule which can bind effectively at the interaction
points identified and form common class of inhibitors.
In this study, differences were also observed at amino
acid level i.e. two different amino acids present in two
different enzymes share the same physicochemical prop-
erty. This can be exploited in specific drug design, as
was done earlier in the case of COX-2.
Methods
Preparation of enzyme-substrate complexes
In this study, AA metabolizing enzymes LOXs and COXs
were considered collectively for binding site analysis. Two
COX enzymes namely, COX-1 (PDB id. 1DIY) [25] and
COX-2 (PDB id. 3HS5) [26] co-crystallised with AA were
obtained from PDB (www.rcsb.org/pdb). To date struc-
tural information of only five LOXs are available: two iso-
forms from soybean, LOX-1 (PDB id. 1YGE) [27] and
LOX-3 (PDB id. 1IK3) [28]; three animal LOX isoforms
rabbit reticulocyte 15-LOX (PDB id. 1LOX) [29] and hu-
man 5-LOX (PDB id. 3O8Y) [30] and 12-LOX (PDB id.
3D3L). All the LOX crystal structures were not co-
crystallized with the substrate, hence to obtain protein-AA
complex docking was performed.
GOLD (Genetic Optimization of Ligand Docking), a
docking program based on genetic algorithm [31] was
used to dock the substrate i.e. AA. The structure of AA
was sketched and minimized using cerius2 and structure
with cis double bonds is obtained in conformational
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was selected. The number of poses for each inhibitor
was set to 100 and early termination was allowed if
the top three bound conformations of a ligand were
within 1.5 Å RMSD. Input parameters of the GOLD
were set to allow octahedral coordination geometry
to iron. After docking, the individual binding poses
of each ligand were observed and their interactions
with the protein were studied. The best and the most
energetically favorable conformation of each ligand
was selected. A four-stage protocol was set up for
energy minimizations of the protein-inhibitor com-
plex [15]. Minimization at each stage was performed
using 100 steps of steepest descent and 1500 steps of
conjugate gradient algorithms for minimization. In
the first stage, water molecules were minimized keep-
ing the inhibitor and protein atoms fixed. This will
relieve any bad contacts involving water molecules in
the initially solvated system. In the second stage the
hydrogen atoms of the whole system were allowed to
relax. This step relaxes the hydrogen atoms prior to
relaxing heavy atoms. In the third stage all the atoms
of the inhibitor and the solvent are allowed to move
during optimization. This stage establishes the pre-
ferred interactions. In the fourth and final stage, all
the protein atoms within 15 Å from the center of
the inhibitor (water molecules, protein atoms and the
ligand) were allowed to relax. After optimization of
the protein-ligand complexes, they were visualized
and studied using InsightII.
Comparative analysis of binding sites using MultiBind
After obtaining the LOX-AA complexes, to compare the
binding pockets and to determine the common features
which facilitate the binding of the same substrate, the
program MultiBind was used [32]. MultiBind reveals the
common physico-chemical patterns (receptor based phar-
macophore) that may be responsible for the binding of a
small molecule in a set of binding sites. Molecular surface
of the binding site is determined by solvent accessible sur-
face points that are located from the surface of the bound
molecule [33]. The program further performs multiple
alignments of binding sites and recognizes conserved
physicochemical and geometrical patterns directing the
common binding. MultiBind develops receptor based
pharmacophore model for the proteins of interest. Each
amino acid in a binding site is represented by points in 3D
space termed pseudocenters as described by Schmitt et al.
[34]. Each pseudocenter represents one of the following
physicochemical properties important for protein–ligand
interactions: hydrophobic, ALI, PII, DON, ACC and DAC.
It will superimpose the binding sites in a manner that will
maximize the physicochemical score of the matched prop-
erties. High MultiBind score implies high similarities inthe physicochemical properties of the binding sites of the
proteins compared.
First, the binding sites were compared pair wise. The
COX enzymes, COX-1 and COX-2 were compared with
each other. Further, AA binding site of COX-2 was com-
pared with all the LOXs. Later multiple binding site
studies were performed; comparison of 6 enzymes elim-
inating one enzyme at a time from the MultiBind during
run time. There were six different combinations possible
in this stage. Later the alignment between 5 binding sites
was performed. This study had 21 possible combinations.
In the same way combinations of four, three and two en-
zyme binding sites were also performed.
Verification of COX-2/5-LOX and 5-LOX/15-LOX models
generated
Prior to the application of the developed models for
drug design, validation of the same is very important.
The dual inhibitors of COX-2/5-LOX design have great
therapeutic importance and hence the common receptor
based models obtained for COX-2/5-LOX were further
validated by docking studies. A COX-2/5-LOX dual in-
hibitor, Licofelone was used for docking studies. If the
receptor based pharmacophore model generated for
COX-2/5-LOX is accurate, Licofelone should form inter-
actions with the common physico chemical features
identified. ABT-761, a specific 5-LOX inhibitor was also
docked and its interactions with 5-LOX and 15-LOX
were compared to the models obtained. The molecules
were docked using the methodology explained earlier
and their interactions were investigated and visualized
using Accelrys Discovery Studio Visualiser 3.0.
Additional file
Additional file 1: Exploration of binding site pattern in arachidonic
acid metabolizing enzymes, lipoxygenases and cycloxygenases.
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